Jian Weiying, Feng Minyan, Li Jin
Department of Mental Health, Guangzhou United Family Hospital, Guangzhou, CHN.
Department of Pharmacy, Guangzhou United Family Hospital, Guangzhou, CHN.
Cureus. 2024 Jul 16;16(7):e64655. doi: 10.7759/cureus.64655. eCollection 2024 Jul.
Lemborexant is a competitive antagonist of dual orexin receptors indicated for the treatment of adult patients with insomnia characterized by difficulties with sleep onset and/or sleep maintenance that occur at least three nights per week for ≥3 months, although there is adequate opportunity for sleep. There has been no published study of its efficacy and safety in treating patients from China with insomnia. In this case report, we present four adult patients from China with insomnia who were successfully treated with add-on lemborexant or switched from benzodiazepines or Z-drugs to lemborexant. None of the four patients experienced any discomforts related to lemborexant use. In conclusion, lemborexant treatment was effective and safe in treating the four patients from China with insomnia in this case report, and more studies are warranted to further assess the efficacy and safety of lemborexant in treating patients from China with insomnia.
伦博瑞生是一种双重食欲素受体竞争性拮抗剂,适用于治疗成年失眠患者,这些患者的特征为入睡困难和/或睡眠维持困难,每周至少出现三个晚上,持续≥3个月,尽管有充足的睡眠机会。目前尚无关于其治疗中国失眠患者有效性和安全性的已发表研究。在本病例报告中,我们介绍了四名来自中国的成年失眠患者,他们通过加用伦博瑞生或从苯二氮䓬类药物或Z类药物转换为伦博瑞生而成功得到治疗。这四名患者均未出现与使用伦博瑞生相关的任何不适。总之,在本病例报告中,伦博瑞生治疗对四名来自中国的失眠患者有效且安全,需要更多研究以进一步评估伦博瑞生治疗中国失眠患者的有效性和安全性。